Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C

Journal of Acquired Immune Deficiency Syndromes

Volumn 56, Issue 1, 2011, Pages 9-15

  Coetzer, Mia ^a   Nedellec, Rebecca ^a   Cilliers, Tonie ^b,d   Meyers, Tammy ^c   Morris, Lynn ^b   Mosier, Donald E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d TROY Molecular Technologies   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR8; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; FORMYLPEPTIDE RECEPTOR LIKE 1; PROTEIN APJ; PROTEIN CMKLR1; PROTEIN GPCR1; PROTEIN GPR15; PROTEIN RDC 1; UNCLASSIFIED DRUG;

ALGORITHM; ARTICLE; CHILD; ENVELOPE GENE; GENE SEQUENCE; GENETIC RECOMBINATION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ENVELOPE;

CHILD; CLONING, MOLECULAR; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHENOTYPE; PHYLOGENY; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECEPTORS, FORMYL PEPTIDE; RECEPTORS, LIPOXIN; RECOMBINATION, GENETIC;

EID: 78650702252     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181f63906     Document Type: Article

References (51)

1. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis. 1994;169:968-974.
2. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-628.
3. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med. 1997;3:1259-1265.
4. Abebe A, Demissie D, Goudsmit J, et al. HIV-1 subtype C syncytium- and non-syncytium-inducing phenotypes and coreceptor usage among Ethiopian patients with AIDS. AIDS. 1999;13:1305-1311.
5. Ping LH, Nelson JA, Hoffman IF, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol. 1999;73:6271-6281.
6. Cilliers T, Nhlapo J, Coetzer M, et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003;77:4449-4456.
7. Coetzer M, Cilliers T, Ping LH, et al. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology. 2006; 356:95-105.
8. Batra M, Tien PC, Shafer RW, et al. HIV type 1 envelope subtype C sequences from recent seroconverters in Zimbabwe. AIDS Res Hum Retroviruses. 2000;16:973-979.
9. Singh A, Page T, Moore PL, et al. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C isolates. Virology. 2009;393:56-67.
10. Michler K, Connell BJ, Venter WD, et al. Genotypic characterization and comparison of full-length envelope glycoproteins from South African HIV type 1 subtype C primary isolates that utilize CCR5 and/or CXCR4. AIDS Res Hum Retroviruses. 2008;24:743-751.
11. Coetzer M, Cilliers T, Papathanasopoulos M, et al. Longitudinal Analysis of HIV Type 1 Subtype C Envelope Sequences from South Africa. AIDS Res Hum Retroviruses. 2007;23:316-321.
12. Kassaye S, Johnston E, McColgan B, et al. Envelope coreceptor tropism, drug resistance, and viral evolution among subtype C HIV-1-infected individuals receiving nonsuppressive antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;50:9-18.
13. White EJ, McColgan B, Kassaye S, et al. Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5). AIDS. 2010;24:1063-1064.
14. Patel MB, Hoffman NG, Swanstrom R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J Virol. 2008;82:903-916.
15. Carrillo A, Ratner L. Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants. J Virol. 1996;70:1301-1309.
16. Koito A, Harrowe G, Levy JA, et al. Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol. 1994;68:2253-2259.
17. Pastore C, Nedellec R, Ramos A, et al. Human immunodeficiency virus type 1 coreceptor switching: V1/V2 gain-of-fitness mutations compensate for V3 loss-of-fitness mutations. J Virol. 2006;80:750-758.
18. Coetzer M, Nedellec R, Salkowitz J, et al. Evolution of CCR5 use before and during coreceptor switching. J Virol. 2008;82:11758-11766.
19. Jensen MA, Coetzer M, van't Wout AB, et al. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope v3 sequences. J Virol. 2006;80:4698-4704.
20. Nedellec R, Coetzer M, Shimizu N, et al. Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by Human Immunodeficiency Virus type 1 subtype. J Virol. 2009;83:8353-8363.
21. Choge I, Cilliers T, Walker P, et al. Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006;22:458-465.
22. Gao F, Morrison SG, Robertson DL, et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization. J Virol. 1996;70:1651-1667.
23. Connor RI, Chen BK, Choe S, et al. Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology. 1995;206:935-944.
24. Soda Y, Shimizu N, Jinno A, et al. Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line. Biochem Biophys Res Commun. 1999;258:313-321.
25. Zhang M, Gaschen B, Blay W, et al. Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology. 2004;14:1229-1246.
26. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999;73:10489-10502.
27. Moore PL, Ranchobe N, Lambson BE, et al. Limited neutralizing antibody specificities drive neutralization escape in early HIV-1 subtype C infection. PLoS Pathog. 2009;5:e1000598.
28. Bozek K, Thielen A, Sierra S, et al. V3 loop sequence space analysis suggests different evolutionary patterns of CCR5- and CXCR4-tropic HIV. PLoS One. 2009;4:e7387.
29. Hoffman NG, Seillier-Moiseiwitsch F, Ahn J, et al. Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol. 2002;76:3852-3864.
30. Pollakis G, Kang S, Kliphuis A, et al. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem. 2001;276:13433-13441.
31. Dong XN, Chen X, Chen Y, et al. Short communication: HIV type 1 phenotype, tropism, and sequence patterns: association and preference. AIDS Res Hum Retroviruses. 2005;21:234-238.
32. Masciotra S, Owen SM, Rudolph D, et al. Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression. AIDS. 2002;16:1887-1898.
33. Bjorndal A, Sonnerborg A, Tscherning C, et al. Phenotypic characteristics of human immunodeficiency virus type 1 subtype C isolates of Ethiopian AIDS patients. AIDS Res Hum Retroviruses. 1999;15:647-653.
34. Gray L, Sterjovski J, Churchill M, et al. Uncoupling coreceptor usage of human immunodeficiency virus type 1 (HIV-1) from macrophage tropism reveals biological properties of CCR5-restricted HIV-1 isolates from patients with acquired immunodeficiency syndrome. Virology. 2005;337:384-398.
35. Repits J, Oberg M, Esbjornsson J, et al. Selection of human immunodeficiency virus type 1 R5 variants with augmented replicative capacity and reduced sensitivity to entry inhibitors during severe immunodeficiency. J Gen Virol. 2005;86(Pt 10):2859-2869.
36. Shimizu N, Tanaka A, Oue A, et al. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV. AIDS. 2009; 27:761-769.
37. Sullivan WM, Dorr P, Perros M, et al. Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells. Arch Virol. 2008;153:363-366.
38. Zhang YJ, Moore JP. Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry? J Virol. 1999;73:3443-3448.
39. Dash PK, Siddappa NB, Mangaiarkarasi A, et al. Exceptional molecular and coreceptor-requirement properties of molecular clones isolated from an Human Immunodeficiency Virus Type-1 subtype C infection. Retrovirology. 2008;5:25.
40. Cilliers T, Willey S, Sullivan WM, et al. Use of alternate coreceptors on primary cells by two HIV-1 isolates. Virology. 2005;339:136-144.
41. Gorry PR, Dunfee RL, Mefford ME, et al. Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote. Virology. 2007;362:163-178.
42. Jetzt AE, Yu H, Klarmann GJ, et al. High rate of recombination throughout the human immunodeficiency virus type 1 genome. J Virol. 2000;74:1234-1240.
43. Galetto R, Moumen A, Giacomoni V, et al. The structure of HIV-1 genomic RNA in the gp120 gene determines a recombination hot spot in vivo. J Biol Chem. 2004;279:36625-36632.
44. Pollakis G, Abebe A, Kliphuis A, et al. Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals. J Virol. 2004;78:2841-2852.
45. Charpentier C, Nora T, Tenaillon O, et al. Extensive recombination among human immunodeficiency virus type 1 quasispecies makes an important contribution to viral diversity in individual patients. J Virol. 2006;80:2472-2482.
46. Kemal KS, Foley B, Burger H, et al. HIV-1 in genital tract and plasma of women: compartmentalization of viral sequences, coreceptor usage, and glycosylation. Proc Natl Acad Sci USA. 2003;100:12972-12977.
47. Mild M, Esbjornsson J, Fenyo EM, et al. Frequent intrapatient recombination between human immunodeficiency virus type 1 R5 and X4 envelopes: implications for coreceptor switch. J Virol. 2007;81:3369-3376.
48. Salemi M, Burkhardt BR, Gray RR, et al. Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies. PLoS ONE. 2007;2:e950.
49. Lengauer T, Sander O, Sierra S, et al. Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol. 2007;25:1407-1410.
50. Low AJ, Dong W, Chan D, et al. Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS. 2007;21:F17-F24.
51. Poveda E, Briz V, Roulet V, et al. Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. AIDS. 2007;21:1487-1490.